Civitas Therapeutics IPO Research Information

Civitas Therapeutics IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Civitas Therapeutics, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Civitas Therapeutics	CVTS - NASDAQ	$14.00-$16.00	$0.00	$0.00	5 million	9/25/2014
Underwriter(s): J.P. Morgan, BofA Merrill Lynch
Co-Manager(s): Cowen and Company, Oppenheimer & Co.
Industry:
Filing(s): Filed 2014-08-26 Terms Added 2014-09-15

About Civitas Therapeutics (adapted from Civitas Therapeutics prospectus):
They are a biopharmaceutical company focused on developing and commercializing transformative therapeutics using our proprietary ARCUS technology, with an initial focus on treating debilitating OFF episodes, the unpredictable re-emergence of symptoms, in patients with Parkinson's disease, or PD.

This description is adapted from Civitas Therapeutics prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as Civitas Therapeutics "CVTS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.